Blueshift Asset Management, LLC - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 171 filers reported holding BRIDGEBIO PHARMA INC in Q2 2022. The put-call ratio across all filers is 0.46 and the average weighting 0.3%.

Quarter-by-quarter ownership
Blueshift Asset Management, LLC ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q3 2023$434,630
+95.8%
16,482
-24.5%
0.26%
+1185.0%
Q1 2022$222,00021,8300.02%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q2 2022
NameSharesValueWeighting ↓
Aisling Capital Management LP 6,068,125$100,609,51348.41%
Kohlberg Kravis Roberts & Co. L.P. 31,060,971$514,990,89915.50%
M28 Capital Management LP 304,700$5,051,9265.71%
Cormorant Asset Management, LP 4,557,414$75,5624.98%
Octagon Capital Advisors LP 1,338,160$22,186,6933.19%
Ikarian Capital, LLC 594,686$9,859,8942.24%
Affinity Asset Advisors, LLC 389,800$6,462,8842.13%
VIKING GLOBAL INVESTORS LP 26,620,991$441,376,0312.07%
Ikarian Capital, LLC 549,600$9,112,3682.07%
Affinity Asset Advisors, LLC 320,000$5,305,6001.75%
View complete list of BRIDGEBIO PHARMA INC shareholders